{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:42:51Z","timestamp":1791070971196,"version":"4.1.0"},"reference-count":23,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study is to investigate whether sitagliptin can be used as an\n                        initial drug for T2DM and to evaluate its effects on metabolic parameters in\n                        relation to its glycemic efficacies. The subjects received\n                        25\u221250\u2009mg\/day sitagliptin monotherapy (n=69).\n                        At 3 months, they were divided into three groups (n=23 each)\n                        according to the novel parameter called \u201cA1c index\u201d which is\n                        designed to assess glycemic efficacy. The metabolic parameters were compared\n                        between good-responders and poor-responders. These two groups acted as a\n                        control each other. In the overall subjects, efficient reductions of HbA1c\n                        (10.16\u20138.22%) were observed with few adverse events.\n                        Significant correlations were seen between the A1c index and changes of\n                        (\u2206)nonHDL-C (R=0.250) or \u2206LDL-C (R=0.368).\n                        At baseline, T-C, nonHDL-C and BMI levels were significantly lower in\n                        good-responders than poor-responders. At 3 months, in good-responders, HbA1c\n                        levels effectively decreased (11.03\u20137.00%). Indexes for\n                        insulin sensitivity\/resistance [HOMA-R and 20\/(C-peptide x\n                        FBG)] and beta-cell function (HOMA-B and CPR-index) ameliorated. T-C,\n                        nonHDL-C and LDL-C significantly decreased, while BMI increased. However, in\n                        poor-responders, no changes in these parameters were noted. Collectively,\n                        these results suggest that 1) Sitagliptin can be used as a first-line drug\n                        for T2DM and its glycemic efficacy is linked to some atherogenic lipids. 2)\n                        Those with lower T-C, nonHDL-C and BMI appear to respond better with this\n                        drug. 3) Good glycemic efficacy of sitagliptin is medicated through reduced\n                        insulin resistance as well as enhanced beta-cell functions. Body weight\n                        increased, while some atherogenic cholesterol decreased in\n                        good-responders.<\/jats:p>","DOI":"10.1055\/a-1304-3430","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T01:03:04Z","timestamp":1606352584000},"page":"157-165","source":"Crossref","is-referenced-by-count":6,"title":["Sitagliptin as an Initial Therapy and Differential Regulations of\n                    Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2\n                    Diabetes"],"prefix":"10.1055","volume":"71","author":[{"given":"Eiji","family":"Kutoh","sequence":"additional","affiliation":[{"name":"Biomedical Center, Tokyo, Japan"},{"name":"Division of Diabetes and Endocrinology, Department of Internal\n                    Medicine, Gyoda General Hospital, Saitama, Japan"},{"name":"Division of Diabetes and Metabolism, Department of Internal Medicine,\n                    Higashitotsuka Memorial Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra N.","family":"Kuto","sequence":"additional","affiliation":[{"name":"Biomedical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askuka","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Internal\n                    Medicine, Gyoda General Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyunka","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Internal\n                    Medicine, Gyoda General Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Internal\n                    Medicine, Gyoda General Hospital, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"American Diabetes Association. Pharmacologic approaches to glycemic treatment:\n                    Standards of Medical Care in Diabetes \u2013 2020","volume":"43","author":"E Bosi","year":"2020","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fendo.2019.00376","article-title":"DPP-4 Inhibition and the Path to Clinical Proof","volume":"10","author":"B Ahr\u00e9n","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1592\/phco.30.5.463","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes\n                    mellitus","volume":"30","author":"J J Neumiller","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1210\/jc.2009-2741","article-title":"Time for testing incretin therapies in early type 1 diabetes?","volume":"95","author":"E Bosi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/13543784.2019.1592156","article-title":"Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in\n                    the treatment of diabetic kidney disease","volume":"28","author":"H Davis","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/14779072.2015.1046840","article-title":"Sitagliptin for type 2 diabetes: A 2015 update","volume":"13","author":"M Lee","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40265-013-0169-1","article-title":"Sitagliptin: A review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"G L Plosker","year":"2014","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: systematic review and meta-analysis","volume":"29","author":"M Monami","year":"2012","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/ijcp.12697","article-title":"Distinct glucose-lowering properties in good responders treated with sitagliptin\n                    and alogliptin","volume":"69","author":"E Kutoh","year":"2015","journal-title":"Int J Clin Pract"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/dom.13940","article-title":"Effects of treatment with metformin and\/or sitagliptin on beta-cell\n                    function and insulin resistance in prediabetic women with previous gestational\n                    diabetes","volume":"22","author":"G Daniele","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40268-017-0179-7","article-title":"Canagliflozin as an initial therapy in drug-na\u00efve subjects with type 2\n                    diabetes mellitus: A potential involvement of atherogenic lipids in its glycemic\n                    efficacy","volume":"17","author":"E Kutoh","year":"2017","journal-title":"Drugs R D"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from\n                    fasting plasma glucose and insulin concentrations in man","volume":"28","author":"D R Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e3544","DOI":"10.7717\/peerj.3544","article-title":"The earth is flat (p>0.05): Significance thresholds and the crisis of\n                    unreplicable research","volume":"5","author":"V Amrhein","year":"2017","journal-title":"PeerJ"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5414\/CP203513","article-title":"Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes:\n                    A potential link between uric acid and pancreatic \u03b2-cell function","volume":"57","author":"E Kutoh","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1507\/endocrj.K11E-096","article-title":"Dynamics of plasma active GLP-1 versus insulin and glucose concentrations during\n                    GLP-1 infusion in rat model of postprandial hyperglycemia","volume":"58","author":"J Eiki","year":"2011","journal-title":"Endocr J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1172\/JCI45680","article-title":"Dynamics of insulin secretion and the clinical implications for obesity and\n                    diabetes","volume":"121","author":"S Seino","year":"2011","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2337\/diacare.25.10.1845","article-title":"Fasting and postchallenge glycemia and cardiovascular disease risk: The\n                    Framingham Offspring Study","volume":"25","author":"J B Meigs","year":"2002","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diabetes.54.1.1","article-title":"Postprandial hyperglycemia and diabetes complications: Is it time to treat?","volume":"54","author":"A Ceriello","year":"2005","journal-title":"Diabetes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13182","article-title":"Factors associated with the glucose-lowering efficacy of sitagliptin in Japanese\n                    patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical\n                    trials","author":"N Tajima","year":"2019","journal-title":"J Diabetes Investig"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2840-12-21","article-title":"20\/(fasting C-peptide\u00d7fasting plasma glucose) is a simple and\n                    effective index of insulin resistance in patients with type 2 diabetes mellitus:\n                    A preliminary report","volume":"12","author":"T Ohkura","year":"2013","journal-title":"Cardiovascular Diabetology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3810\/pgm.2011.01.2244","article-title":"Differential regulations of lipid profiles between Japanese responders and\n                    nonresponders treated with pioglitazone","volume":"123","author":"E Kutoh","year":"2011","journal-title":"Postgrad Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"TECOS study group. effect of sitagliptin on cardiovascular outcomes in type 2\n                    diabetes","volume":"373","author":"J B Green","year":"2015","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/dom.12264","article-title":"SUCCESS Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor\n                    sitagliptin compared with \u03b1-glucosidase inhibitor in Japanese patients\n                    with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2):\n                    A multicenter, randomized, open-label, non-inferiority trial","volume":"16","author":"K Kobayashi","year":"2014","journal-title":"Diabetes Obes Metab"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1304-3430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T23:44:57Z","timestamp":1614123897000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1304-3430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":23,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,2,23]]},"published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1304-3430","relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]}}}